BTAIQ — BioXcel Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.53m
- $92.14m
- $0.64m
U.S. STOCKS ON THE MOVE-American Eagle Outfitters, gold miners, EPAM
U.S. STOCKS ON THE MOVE -Burlington Stores, Berkshire Hathaway, Bioventus
BioXcel jumps after mid-stage trial shows drug eases opioid withdrawal symptoms
Brief: Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal
U.S. STOCKS ON THE MOVE-Moderna, Seagate, Western Digital
U.S. STOCKS ON THE MOVE -Alignment Healthcare, Capricor Therapeutics, silver miners
U.S. STOCKS ON THE MOVE-Netflix, ServiceNow, D.R. Horton
Brief: BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion
BioXcel seeks FDA nod for at‑home agitation treatment; shares fall
BioXcel Therapeutics Q3 revenue misses analyst expectations
Brief: BioXcel Therapeutics Q3 Basic EPS USD -2.18 Vs. IBES Estimate USD -1.24
Brief: BioXcel Therapeutics Inc - Updates On sNDA Submission For IGALMI Label Expansion - SEC Filing
Brief: Bioxcel Therapeutics Regains Compliance With Nasdaq Market Value Of Listed Securities Requirements
U.S. STOCKS ON THE MOVE-CrowdStrike, Nvidia, EchoStar
U.S. STOCKS ON THE MOVE-Aspen, Abercrombie & Fitch, Slide Insurance
U.S. STOCKS ON THE MOVE-Kohl's, J.M. Smucker, Prologis
BioXcel Therapeutics rises after agitation drug meets main goal in at-home study
BioXcel's agitation drug meets main goal in at-home study (updated)
BioXcel's agitation drug meets main goal in at-home study